Summary Resistant glucan (RG) is a water-soluble polysaccharide resistant to hydrolysis by digestive enzymes in the human gastrointestinal system. RG mixture (RGM) contains more than 75% RG as dietary fi ber and other saccharides. The effects of ingestion of 3.3, 6.6, and 13.2 g/d of RGM (containing of 2.5, 5.0, and 10.0 g/d RG as dietary fi ber) on the fecal properties and the frequency of defecation were investigated in 60 female volunteers with constipation. The study was designed as a randomized, single-blinded, and placebo-controlled parallel-group trial. Each subject consumed RGM or a placebo (digestible maltodextrin) for 2 wk. Questionnaire data on the effects on bowel movement were analyzed according to defecation days, defecation frequency, fecal volume, fecal shapes, fecal color, fecal odor, and fecal excretory feeling. The results showed signifi cant increases in defecation frequency (pϽ0.05), defecation days (pϽ0.05), and fecal volume (pϽ0.05) during the 13.2 g/d RGM ingestion period. The effects of RGM on defecation days and frequency showed a dose-dependent increase (pϽ0.05). These results suggested that the intake of RGM increased defecation days, defecation frequency, and fecal volume. In the gastrointestinal tract, RGM is useful as a water-soluble dietary fi ber for the improvement of bowel movements.
Dietary fi ber is known to have positive effects on gastrointestinal health and has been reported to reduce disease risk of coronary heart disease, colorectal cancer, and breast cancer (1) . Furthermore, certain types of fi ber can aid in laxation and alleviate constipation (2) . The Ministry of Health, Labour, and Welfare of Japan recommends a reference intake level of dietary fi ber of 20 g per day for men and 18 g per day for women between 18 and 69 y of age. However, many Japanese fail to consume an adequate amount of fi ber, with an average daily intake of 14.2 g per day (3) . Given these low intakes and the associated disease risk, the 2015 Dietary Guidelines for Japanese recognized fi ber as a nutrient for which intake is lacking and encouraged efforts to increase dietary intake.
A lack of dietary fi ber causes symptoms of constipation that over the long term can potentially promote bowel and metabolism diseases (4) . Therefore, laxation is an important index for health. Generally, two classifi cations of fi ber exist, soluble (e.g., gums, pectins) and insoluble (e.g., cellulose, wheat bran) (5) . Both are found to improve bowel movement (6) (7) (8) . However, insoluble and high-viscosity soluble fi bers have problems such as texture and taste when used for foods or beverages. In recent years, various low-viscosity water-soluble dietary fi bers, including resistant maltodextrin (RMD), polydextrose (PDX), and resistant glucan (RG), have been developed for use in healthy food and beverage products (9) (10) (11) .
We recently developed a novel, simple and effi cient procedure to obtain a type of water-soluble dietary fi ber, resistant glucan mixture (RGM) from glucose syrup, using activated carbon as a catalyst of polycondensation reaction (9) . RGM has several unique features: (i) RGM is a highly branched, randomly bonded polysaccharide composed of only glucose units. The molecule contains all possible combinations of ␣-and ␤-linked 1,2-, 1,3-, 1,4-, and 1,6-glycosidic linkages (Fig. 1); (ii) RGM has lower viscosity compared with other soluble dietary fi bers such as pectin, gum and glucomannan; (iii) RGM has low color, a slightly sweet taste, and no odor, making it suitable for use in food; (iv) RGM, similar to polydextrose, is resistant to hydrolysis by mammalian digestive enzymes in the small intestine.
Laxation and alleviation of constipation by PDX and RMD has been reported (10) (11) (12) (13) . However, RGM is a new material and its physiological effects on humans are untested. The objective of the present study was to evaluate the effects of RGM (containing not less than 75% dietary fi ber) on the frequency and feeling of defecation in human subjects.
MATERIALS AND METHODS
Design and subjects. The study was carried out at C'est la vie Shinbashi Clinic (Tokyo, Japan) and was approved by the Institutional Review Board of C'est la vie Shinbashi Clinic (25 February 2014) before its launch. Furthermore, the study was conducted in accordance with the guidelines of the Declaration of Helsinki, and informed consent was obtained from all participants.
Participants. Study participants were female volunteers (nϭ60) who completed a questionnaire related to previous disease and administration of drugs, a physical, and a medical interview by a doctor. Participants between 20 and 60 y of age were recruited for the study according to fi xed inclusion and exclusion criteria. The inclusion criteria were a tendency for constipation at two to four instances of defecation per week. The exclusion criteria included the following: use of drugs, functional foods, cosmetics, or instruments that may have infl uenced the outcomes of the study; consumption of large amounts of foods such as lactic acid bacteria beverage, food containing lactic acid bacteria or natto bacteria, lactic acid bacteria preparation, dietary fi berenriched food, sugar alcohols, and oligosaccharides; current treatment for digestive diseases that affect the study outcomes; a surgical history involving the digestive system (except appendectomy); current pregnancy or suspected pregnancy; a current illness or the possibility of developing serious side effects; and inappropriacy, as deemed by a doctor.
Test samples. In this experiment, the RGM (product name; Fit Fiber #80P) was manufactured by Nihon Shokuhin Kako Co., Ltd. The dietary fi ber content of the RGM in this experiment was 80.4% (as dried solid) determined by AOAC Offi cial Method 2001.03, an enzymatic high-performance liquid chromatography method. The partial hydrolysates of starch Pinedex no.2, digestible maltodextrin, was from Matsutani Chemical Industry (Hyogo, Japan). The subjects consumed 13.2 g of the powdered dietary fi ber or maltodextrin dissolved in 100 mL of water. Four types of test samples were prepared with RGM (0, 3.3, 6.6, and 13.2 g) and maltodextrin (13.2, 9.9, 6.6, and 0 g), respectively. To achieve equality of appearance and fl avor, adequate volumes of caramel were added to the powder. Table 1 shows analysis values of the nutrient compositions.
Experimental design. The study was designed as a randomized, single-blinded, and placebo-controlled parallel-group trial. The RGM intake schedule is shown in Fig. 2 and participants' characteristics are listed in Table  2 . Participants were divided into four groups of 15 each. After a 2-wk observation period, each volunteer was administered a placebo (13.2 g of maltodextrin per day) for 2 wk. Following this period, each subject was administered 3.3, 6.6, or 13.2 g of RGM per day for 2 wk.
With respect to food intake, subjects were asked to keep to their habitual diet. However, because of the study substance probably affecting fl ora, other food products with similar effects were prohibited during the whole study. Therefore, food items containing preand pro-biotics, and fi ber were not allowed. Subjects recorded a daily questionnaire on their diet, prescriptions and health status during the entire study period.
Subjects were asked to complete a questionnaire related to stool condition after ingestion at each dose level. Additionally, defecation conditions (defecation days, defecation frequency, fecal volume, fecal shape, fecal color, fecal odor, and fecal excretory feeling) were assessed in records.
Statistical analyses. Statistical analyses were performed using IBM SPSS Statistics, Version 21. The data were analyzed by the Wilcoxon signed-rank test and analysis of variance (ANOVA, repeated measurement). For statistical analyses, the Williams test was performed using the statistics software MEPHAS (Osaka University, Osaka, Japan, August 16, 2015) . Data were analyzed for dose-related trends by the Williams test. In terms of subject allocation, no items showed any signifi cant difference. All of the reported p-values were one-tailed and considered statistically signifi cant at the 0.05 level.
RESULTS

Exclusion from the study
No participant withdrew from the study during the examination period. Additionally, no potential participant was excluded on the basis of the exclusion criteria of the study. No abnormal symptoms related to the physical condition of the study participants were observed during any of the examination periods for RGM intake. Table 3 shows the results of the defecation conditions. The data presented represent the mean values per week for each subject. When ingestion periods 1 and 2 are compared, the defecation days, defecation frequency, and fecal volume for the RGM 13.2 g/d intake group were signifi cantly higher than for the placebo intake group (pϽ0.05). However, no signifi cant differences in defecation frequency or defecation days between the placebo intake group and the RGM 3.3 g/d and 6.6 g/d intake groups were noted. The amount of change during ingestion period 2 is shown in Fig. 3 . The effect of RGM on defecation days and defecation frequency was dosedependent (pϽ0.05). There were no signifi cant changes observed in fecal shape, color, odor, or excretory feeling in terms of fecal volume or visual characteristics.
Effect on bowel movement
DISCUSSION
In recent years, many people have suffered from constipation because of the stress of daily life and a lack of dietary fi ber related to Western-style foods in Japan (14, 15) . Constipation not only causes abdominal discomfort, but also increases the risk of colon cancer, given the increased spoilage substances producing harmful bacteria in the intestine and the increased contact time.
The effects of consuming 3.3, 6.6, and 13.2 g/d of RGM (containing of 2.5, 5.0, and 10 g/d RG as dietary fi ber) on fecal properties and defecation frequency were investigated in 60 female participants with constipation. The defecation days and defecation frequency during the period of RGM supplementation as dietary fi ber at a dose of 10 g/d were signifi cantly higher than for the placebo intake group (pϽ0.05). Given the study blinding, these results are not psychological effects on the volunteers. During ingestion period 2, the effect of RGM on defecation days and frequency was dose-dependent.
PDX and RMD have benefi cial effects on bowel function (16) (17) (18) (19) by increasing stool bulk and frequency, improving stool consistency, and making defecation easier. Because of the highly branched chain structures containing ␣-and ␤-1,2-, 1,3-, 1,4-and 1,6-linkages, PDX and RMD are only partially degraded in the gut (12, 20) . Therefore, increased stool weight is a result of increased indigestible mass in the gut, along with increments of total bacterial mass. We reported that RG shows resistance to hydrolysis by digestive enzymes in the human gastrointestinal system in in vitro studies (9) . We hypothesize that the structure of RGM was similar to that in PDX and most of the RG reaches the large intestine.
Fermentation of PDX and RMD leads to the growth of favorable microfl ora, diminished putrefactive microfl ora, enhanced production of short-chain fatty acids, and suppressed production of carcinogenic metabolites (12, 13) . Additionally, PDX is known to have prebiotic effects (21) . We presumed that part of the RGM is available for fermentation by intestinal bacteria in the same way as PDX and RMD, leading to the production of short-chain fatty acids. Accordingly, RGM decreases the pH in the large intestines and stimulates bowel peristalsis. Our future research will focus on the infl uence of the fermentation of RGM in the digestive tract.
These results suggest that the intake of RGM has benefi cial effects for constipated females in increasing fecal volume, defecation days, and defecation frequency. RGM appears to be a safe, useful food material to compensate for the lack of dietary fi ber.
